Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 62, Number 8, April 27, 2004
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Easterford, K.
Right arrow Articles by Duncan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Easterford, K.
Right arrow Articles by Duncan, S.
Related Collections
Right arrow PET
Right arrow Parkinson's disease/Parkinsonism
Right arrow All Epilepsy/Seizures
Right arrow Antiepileptic drugs
NEUROLOGY 2004;62:1435-1437
© 2004 American Academy of Neurology
Brief Communications

Reversible parkinsonism with normal ß-CIT-SPECT in patients exposed to sodium valproate

K. Easterford, BSc MB, ChB, P. Clough, MB ChB, MS, M. Kellett, MRCP, K. Fallon, MB BS, MRCGP and S. Duncan, MD FRCPI

From the Manchester School of Medicine and Dentistry (K. Easterford), Manchester, UK; David Lewis Centre (P. Clough), Alderley Edge, Cheshire, UK; Greater Manchester Neurosciences Centre (Drs. Duncan and Kellett), Hope Hospital, Salford, UK; and general practitioner (Dr. Fallon), Shevington Surgery, Wigan, UK.

Address correspondence and reprint requests to Dr. Susan Duncan, Department of Neurology, Greater Manchester Neurosciences Centre, Hope Hospital, Stott Lane, Salford M6 8 HD, UK; e-mail: susan.duncan{at}srht.nhs.uk

After reports of reversible parkinsonism and cognitive impairment with sodium valproate (VPA), the authors examined 50 consecutive patients taking VPA and 20 patients taking carbamazepine. Three patients taking VPA exhibited unequivocal parkinsonism with Unified Parkinson Disease Rating Scale scores >30. VPA was withdrawn from two patients with improvement of symptoms. Reduction in VPA dosage in the third patient produced no improvement. ß-CIT-SPECT scans were normal, suggesting dopaminergic neuronal loss is not the underlying mechanism.

Received June 12, 2003. Accepted in final form December 10, 2003.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C Zadikoff, R P Munhoz, A N Asante, N Politzer, R Wennberg, P Carlen, and A Lang
Movement disorders in patients taking anticonvulsants
J. Neurol. Neurosurg. Psychiatry, February 1, 2007; 78(2): 147 - 151.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
F Ovsiew
Antiepileptic drugs in psychiatry
J. Neurol. Neurosurg. Psychiatry, December 1, 2004; 75(12): 1655 - 1661.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.